Organisation paid for research Program year 2025 Source: CMS Open Payments

Tyler Research Institute

Neither a doctor nor a teaching hospital

Research payments

$1,276,428

71 payments

Through program year 2025, Tyler Research Institute is reported as receiving $1,276,428 in research payments, across 71 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $83,052 4
2024 Research $281,657 15
2023 Research $361,991 18
2022 Research $171,809 23
2021 Research $228,791 4
2020 Research $149,129 7

Breakdown

Who paid Research payments · program years 2020–2025
  1. E.R. Squibb & Sons, L.L.C. $803,017 24 payments
  2. Celgene Corporation $355,071 21 payments
  3. AbbVie, Inc. $75,045 19 payments
  4. Sanofi US Services Inc. $43,295 7 payments
Studies the money was for Research payments · program years 2020–2025
  1. An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice $169,601 1 payment
  2. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis $164,128 4 payments
  3. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $124,259 5 payments
  4. Phase 2 CD (Primary represents Induction) - A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohns Disease $114,306 1 payment
  5. A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $87,315 1 payment
  6. A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis $75,045 19 payments
  7. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) $56,318 1 payment
  8. Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti $53,717 3 payments
  9. An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice $48,167 1 payment
  10. A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype $43,295 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record